A Review on Golimumab in The Treatment of Psoriatic Arthritis

Jethwa, Hannah; Sultan, Reshma; Abraham, Sonya

doi:10.2217/imt-2017-0063

Cited by 10 publications

(6 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3) Golimumab as it significantly improved the scores of ACR20, ACR50 and ACR70 by 61%, 38% and 21% 26 .…”

Section: Fig 4: Before and After Example Of A Patient With Psoriatic Arthritis Who Underwent Treatment With 200 Mg Filgotinibmentioning

confidence: 97%

See 1 more Smart Citation

Untitled

2021

IJPSR

View full text Add to dashboard Cite

Psoriatic arthritis is an inflammatory condition of the skin and musculoskeletal system with cutaneous psoriasis that leads to joint deformity and disability and is commonly seen in 40-50-year-old population. Clinically, TNF-α inhibitors and JAK inhibitors form the main line of treatment of this rare disorder. A systematic review was conducted via an electronic search of Google Scholar, PubMed, Science Direct, Wiley, Embase, and Cochrane databases till May 2020 using the following keywords: "Psoriatic arthritis", "Atrophic arthritis", "Rheumatoid arthritis". Published literature that explores the therapeutic methods of treating CSOM are included along with data of randomized control trials (RCTs), in-vivo studies and ELISA assays are collated in this review. 43 qualitative studies from 6 databases are included in this systematic review. Of these, 40 studies depict the efficacy of chemically synthesized, nature-derived, monoclonal antibody and recombinant DNA compounds (TNF-α inhibitors, T-cell suppressors, inhibitors of MAP kinase, and JAK) and 3 studies depict the benefits of alternative agents (ZSTK474, gold sodium thiomalate nanoparticles and whole body cryotherapy) in PsA. A critical analysis of the published literature indicates that filgotinib, golimumab, upadacitinib, etanercept, guselkumab, N, N-dimethylsphingosine, and hederagenin are most effective in reducing arthritic pain (by 58 to 80%). This review aims to provide a comprehensive perspective on the role of diverse synthetic, recombinant DNA and nature-based agents in the modulation of inflammatory events and joint tenderness and swelling involved in the complex path physiology of PsA. INTRODUCTION:Psoriatic arthritis (PsA) synonyms: rheumatoid arthritis, rheumatism, and atrophic arthritis is chronic inflammatory arthritis of the joints of the fingers and toes that frequently occurs in association with skin and nail psoriasis 1 . It is characterized by red, dry, itchy, and scaly skin patches and sausage-shaped swelling of the fingers and toes 2 .

show abstract

“…3) Golimumab as it significantly improved the scores of ACR20, ACR50 and ACR70 by 61%, 38% and 21% 26 .…”

Section: Fig 4: Before and After Example Of A Patient With Psoriatic Arthritis Who Underwent Treatment With 200 Mg Filgotinibmentioning

confidence: 97%

“…They were assessed for improvement in the swollen and tender joint count by ACR20, ACR50, and ACR70. The results indicated that golimumab significantly improved the scores of ACR20 (61%), ACR50 (38%), and ACR70 (21%) 26 . Results of anti-psoriatic effects of 100 mg golimumab are depicted in Fig.…”

Section: Monoclonal Antibodiesmentioning

confidence: 98%

Untitled

2021

IJPSR

View full text Add to dashboard Cite

show abstract

“…Adalimumab and golimumab are also fully human recombinant immunoglobulin G1 monoclonal antibodies that specifically target TNF-α. Golimumab has also been approved by the Food and Drug Administration to be used for psoriatic arthritis [ 169 ]. Recently, certolizumab pegol has been used in the treatment of psoriasis.…”

Section: Novel Paradigm In Treatment Targets For Psoriasismentioning

confidence: 99%

Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis

Woo

Cho

Park

2017

IJMS

View full text Add to dashboard Cite

Psoriasis is a complex chronic inflammatory cutaneous disorder. To date, robust molecular mechanisms of psoriasis have been reported. Among diverse aberrant immunopathogenetic mechanisms, the current model emphasizes the role of Th1 and the IL-23/Th17 axis, skin-resident immune cells and major signal transduction pathways involved in psoriasis. The multiple genetic risk loci for psoriasis have been rapidly revealed with the advent of a novel technology. Moreover, identifying epigenetic modifications could bridge the gap between genetic and environmental risk factors in psoriasis. This review will provide a better understanding of the pathogenesis of psoriasis by unraveling the complicated interplay among immunological abnormalities, genetic risk foci, epigenetic modification and environmental factors of psoriasis. With advances in molecular biology, diverse new targets are under investigation to manage psoriasis. The recent advances in treatment modalities for psoriasis based on targeted molecules are also discussed.

show abstract

“…Current treatments include nonsteroidal anti-inflammatory drugs, corticosteroids, and disease-modifying anti-rheumatic drugs (DMARDs) [ 5 – 7 ]. Tumor necrosis factor inhibitors (TNFi) were the first biologic DMARDs (bDMARDs) approved for the treatment of these conditions and have revolutionized pharmacologic treatment by preventing disease progression [ 8 – 10 ].…”

Section: Introductionmentioning

confidence: 99%

“….00(10,253.80) 12,016.40 8675.40 (3755.80) 17,260.40 0.29 SD standard deviation, TB tuberculosis, TNF tumor necrosis factor, IV intravenous, NSAID nonsteroidal anti-inflammatory drug, CCP cyclic citrullinated peptide, DNA deoxyribonucleic acid, RA rheumatoid arthritis, PsA psoriatic arthritis, AS ankylosing spondylitis a Aside from age and sex, which were identified on the index date, characteristics were identified during the 6-month period before and including the index date (baseline period) except where otherwise indicated…”

mentioning

confidence: 99%

Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database

et al. 2020

View full text Add to dashboard Cite

Background and Objective Golimumab is a fully human anti-tumor necrosis factor monoclonal antibody approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). This study estimated rates of prespecified outcomes in patients with RA, PsA or AS initiating golimumab versus matched patients initiating nonbiologic systemic (NBS) medications. Methods Patients enrolled in a US health plan with rheumatic disease who initiated a study medication were accrued between April 2009 and November 2014. Golimumab initiators were matched by propensity score to NBS initiators in a 1:4 ratio. Outcomes were identified through September 2015. As-treated, as-matched, and nested case-control (NCC) analyses were conducted in the matched cohorts. Sensitivity analyses evaluated the impact of residual confounding and nondifferential misclassification of exposure and outcomes. Results Risks of outcomes were similar between golimumab and NBS initiators. In the as-treated analysis, the rate ratio (RR) for depression was elevated during current golimumab use versus golimumab non-use in the NBS cohort [RR 1.45, 95% confidence interval (CI) 1.31-1.61]. This finding was not replicated in as-matched (RR 1.08, 95% CI 0.97-1.19) or NCC (odds ratio 1.01, 95% CI 0.78-1.31) analyses, which focused on incident cases. Sensitivity analyses suggest that depression was sensitive to misclassification, and the RR changed from greater than to less than one across a plausible range of specificity. Conclusions This study suggests that there is no association between exposure to golimumab and an increased risk of prespecified outcomes. Increased depression risk in the as-treated analysis was not replicated in other analyses and may be associated with residual imbalance in baseline history or severity of depression.

show abstract

A Review on Golimumab in The Treatment of Psoriatic Arthritis

Cited by 10 publications

References 43 publications

Untitled

Untitled

Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis

Post-approval Safety Surveillance Study of Golimumab in the Treatment of Rheumatic Disease Using a United States Healthcare Claims Database

Contact Info

Product

Resources

About